CNSY
Cerenome, Inc.
Set alert
- YTD
- -86.67%
- 1 year
- -87.17%
- Open
- 1.76
- Prev close
- 1.74
- Mkt cap
- 12.90M
- Vol
- 47.77K
- Avg vol
- 109.26K
- EPS
- -3.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.66
- High
- 1.76
News
1 day ago globenewswire.com
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Topline data expected in mid-2027 Previously reported interim Phase 2 data showed a 63% improvement in median overall survival versus standard of care in recurrent glioblastoma (13 months vs. 8…
-
3 days ago benzinga.com
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of…
3 days ago globenewswire.com
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be…
1 week ago zacks.com
New Strong Sell Stocks for October 22nd
CANG, CDZI and CNSY have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2026.
-
1 week ago benzinga.com
Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
1 week ago globenewswire.com
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ…
2 weeks ago zacks.com
New Strong Sell Stocks for October 15th
CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
3 weeks ago globenewswire.com
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Cerenome secures Florida Blue agreement for CNSide tumor cell and molecular tests, expanding contracted payer access to approximately 164M covered lives.
3 weeks ago globenewswire.com
Cerenome Launches CNSide® CSF Molecular Profile Tests
HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of…
-
4 weeks ago benzinga.com
Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31
Lake Street analyst Chad Messer maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $50 to $31.
1 month ago seekingalpha.com
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
-
1 month ago benzinga.com
Cerenome Anticipates $1.55M In Payer Billings In Q3
Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer
1 month ago globenewswire.com
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30,…
1 month ago globenewswire.com
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), today announced that management will…
1 month ago globenewswire.com
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY ) (“Cerenome” or the “Company”), announced today that it has signed an…
1 month ago globenewswire.com
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of…
1 month ago benzinga.com
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Darden, ServiceNow, Robinhood, Ibex and Workiva, while cutting targets for McDonald’s, Cerenome and Wingstop.
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
-
1 month ago benzinga.com
Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the…
1 month ago globenewswire.com
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into…
-
2 months ago benzinga.com
Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference
Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal…
2 months ago globenewswire.com
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
2 months ago zacks.com
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
Cerenome (CNSY) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.25 per share a year ago.
-
2 months ago benzinga.com
Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate
Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.85) by 54.12 percent. This is a 718.75 percent decrease over losses of $(0.16)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
2 months ago globenewswire.com
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics,…
2 months ago globenewswire.com
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an…
3 months ago globenewswire.com
Cerenome Launches as an Integrated CNS Oncology Company
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective…